Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

[Ceritinib as First-line Treatment for Advanced Lung Adenocarcinoma 
with COX7A2L-ALK Fusion: A Case Report and Literature Review].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Yuan J;Yuan J;Yuan J; Pan R; Pan R; Zhong W; Zhong W; Wang M; Wang M
  • Source:
    Zhongguo fei ai za zhi = Chinese journal of lung cancer [Zhongguo Fei Ai Za Zhi] 2023 Apr 20; Vol. 26 (4), pp. 319-324.
  • Publication Type:
    Review; Case Reports; English Abstract; Journal Article
  • Language:
    Chinese
  • Additional Information
    • Source:
      Publisher: Zhongguo fei ai za zhi bian ji wei yuan hui Country of Publication: China NLM ID: 101126433 Publication Model: Print Cited Medium: Internet ISSN: 1999-6187 (Electronic) Linking ISSN: 10093419 NLM ISO Abbreviation: Zhongguo Fei Ai Za Zhi Subsets: MEDLINE
    • Publication Information:
      Publication: 2008- : Tianjin Shi : Zhongguo fei ai za zhi bian ji wei yuan hui
      Original Publication: Chendu Shi : Zhongguo fei ai za zhi bian ji wei yuan hui
    • Subject Terms:
      Lung Neoplasms*/drug therapy ; Lung Neoplasms*/genetics ; Lung Neoplasms*/diagnosis ; Adenocarcinoma of Lung*/drug therapy ; Adenocarcinoma of Lung*/genetics; Humans ; Anaplastic Lymphoma Kinase/genetics ; Crizotinib ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Oncogene Proteins, Fusion/genetics
    • Abstract:
      Lung cancer is the most common in incidence and mortality worldwide. With the development of next generation sequencing (NGS) detection technology, more and more patients with rare anaplastic lymphoma kinase (ALK) fusion mutations were detected. A case of advanced lung adenocarcinoma with rare COX7A2L-ALK (C2:A20) fusion detected by NGS was reported in Peking Union Medical College Hospital, and all cases with rare ALK fusion mutations were searched from medical datebase from January 1, 2014 to March 31, 2021, to investigate the treatment of rare ALK fusion mutations with ALK inhibitors. The best response of the patient was assessed as partial response (PR) with Ceritinib treatment. By literature review, 22 cases of rare ALK fusion were reported in 19 articles. Combined with this case, 23 cases were analyzed. The objective response rate (ORR) was 82.6% (19/23) and disease control rate (DCR) was 95.7% (22/23) for rare ALK fusions patients treated with ALK inhibitors. Lung adenocarcinoma patients with rare ALK fusion could benefit from ALK inhibitors.
.
    • References:
      Lung Cancer. 2018 Jan;115:5-11. (PMID: 29290262)
      Mayo Clin Proc Innov Qual Outcomes. 2017 Apr 27;1(1):111-116. (PMID: 30225407)
      Expert Rev Mol Diagn. 2021 Jun;21(6):531-534. (PMID: 33887162)
      J Thorac Oncol. 2019 Sep;14(9):e191-e193. (PMID: 31445731)
      J Thorac Oncol. 2019 Jul;14(7):1255-1265. (PMID: 30851442)
      J Thorac Oncol. 2019 Jun;14(6):e115-e117. (PMID: 31122560)
      Clin Cancer Res. 2009 May 1;15(9):3143-9. (PMID: 19383809)
      Eur Respir J. 2017 Apr 12;49(4):. (PMID: 28404650)
      Clin Cancer Res. 2019 Aug 1;25(15):4712-4722. (PMID: 31028088)
      Genes Chromosomes Cancer. 2012 Jun;51(6):590-7. (PMID: 22334442)
      Onco Targets Ther. 2020 Dec 04;13:12515-12519. (PMID: 33311990)
      J Thorac Oncol. 2018 Nov;13(11):1792-1797. (PMID: 30010043)
      Lung Cancer. 2020 Aug;146:370-372. (PMID: 32527613)
      J Thorac Oncol. 2018 Mar;13(3):e43-e45. (PMID: 29472060)
      Am J Cancer Res. 2020 May 01;10(5):1366-1383. (PMID: 32509385)
      PLoS One. 2012;7(2):e31323. (PMID: 22347464)
      Lung Cancer (Auckl). 2018 Nov 08;9:111-116. (PMID: 30519133)
      Lung Cancer. 2020 Jul;145:211-212. (PMID: 32409002)
      Clin Cancer Res. 2015 Aug 15;21(16):3631-9. (PMID: 25567908)
      J Thorac Oncol. 2014 Apr;9(4):563-6. (PMID: 24736082)
      Lung Cancer. 2013 Nov;82(2):179-89. (PMID: 24011633)
      Oncologist. 2016 Jun;21(6):762-70. (PMID: 27245569)
      Clin Cancer Res. 2011 Apr 15;17(8):2081-6. (PMID: 21288922)
      J Thorac Oncol. 2015 Jun;10(6):e37-9. (PMID: 26001147)
      Lung Cancer. 2020 Apr;142:59-62. (PMID: 32114282)
      J Thorac Oncol. 2017 Dec;12(12):e202-e204. (PMID: 29169525)
      Cancer Biol Ther. 2018;19(11):962-966. (PMID: 30273505)
      Cancer. 2011 Jun 15;117(12):2709-18. (PMID: 21656749)
      Cell Rep. 2016 Aug 30;16(9):2387-98. (PMID: 27545886)
      Lung Cancer. 2019 Nov;137:19-22. (PMID: 31521978)
      Nature. 2007 Aug 2;448(7153):561-6. (PMID: 17625570)
      J Thorac Oncol. 2018 May;13(5):e72-e74. (PMID: 29703539)
      Clin Cancer Res. 2009 Aug 15;15(16):5216-23. (PMID: 19671850)
    • Contributed Indexing:
      Keywords: ALK inhibitors; COX7A2L-ALK fusion mutation; Lung neoplasms; Rare ALK fusion mutation
      Local Abstract: [Publisher, Chinese] 【中文题目：罕见COX7A2L-ALK融合突变
晚期肺腺癌1例病例报告并文献复习】 【中文摘要：肺癌是全世界发病率和死亡率最高的肿瘤，随着下一代测序（next generation sequencing, NGS）检测技术的发展，越来越多的罕见间变性淋巴瘤激酶（anaplastic lymphoma kinase, ALK）融合突变患者被检测出来。本文报道了北京协和医院收治的1例罕见COX7A2L-ALK（C2:A20）融合突变的肺腺癌晚期患者，同时检索2014年1月1日-2021年3月31日发表的罕见ALK融合突变的病例报道，探讨ALK抑制剂对罕见ALK融合突变患者的疗效。本例患者一线给予口服塞瑞替尼后病情好转，疗效评价为部分缓解（partial response, PR）。通过上述检索方法检索出符合文献19篇，共报道22例罕见ALK融合突变，结合本例，对23例进行汇总分析。分析结果显示，ALK抑制剂对罕见ALK融合突变的客观有效率为82.6%（19/23），疾病控制率为95.7%（22/23）。罕见ALK融合突变晚期肺腺癌患者可以从ALK抑制剂治疗中受益。
】 【中文关键词：罕见ALK融合突变；ALK抑制剂；肺肿瘤；COX7A2L-ALK融合突变】.
    • Accession Number:
      EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
      K418KG2GET (ceritinib)
      53AH36668S (Crizotinib)
      0 (Protein Kinase Inhibitors)
      0 (Oncogene Proteins, Fusion)
    • Publication Date:
      Date Created: 20230515 Date Completed: 20230516 Latest Revision: 20230519
    • Publication Date:
      20231215
    • Accession Number:
      PMC10186266
    • Accession Number:
      10.3779/j.issn.1009-3419.2023.102.15
    • Accession Number:
      37183647